Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.

Pulmonary circulation·2016
Same author

Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension).

International journal of cardiology·2015
Same author

Pulmonary arterial hypertension in children: Diagnostic work-up and challenges.

Progress in pediatric cardiology·2011
Same author

Non-congenital heart disease associated pediatric pulmonary arterial hypertension.

Progress in pediatric cardiology·2011
Same author

Pulmonary arterial hypertension: a comparison between children and adults.

The European respiratory journal·2011
Same author

A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Clinical pharmacology and therapeutics·2009

相关实验视频

Updated: Jul 12, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

长期使用前环素治疗肺高血压与相关的先天性心脏缺陷.

E B Rosenzweig1, D Kerstein, R J Barst

  • 1Division of Pediatric Cardiology, Columbia Presbyterian Medical Center, New York, NY, USA. esb14@columbia.edu

Circulation
|April 13, 1999
PubMed
概括

长期的前环素 (PGI2) 治疗显著改善了肺高血压和先天性心脏缺陷患者的血液动力学和生活质量,这些患者没有对传统治疗做出反应. 这表明PGI2是这个患者群的可行治疗选择.

科学领域:

  • 心脏病学 心脏病学
  • 肺部病理学 肺部病理学
  • 儿童心脏病学 儿童心脏病学

背景情况:

  • 肺高血压 (PHT) 与先天性心脏缺陷 (CHD) 是一个复杂的疾病.
  • 长期的前环素 (PGI2) 益处是在初级PHT中确立的,但不是在CHD的PHT中.
  • 在CHD的PHT中PGI2的疗效仍然未被评估.

研究的目的:

  • 评估慢性前列腺素 (PGI2) 在患有肺高血压 (PHT) 和相关先天性心脏缺陷 (CHD) 的患者中的有效性.
  • 在这个人群中,评估PGI2治疗后血液动力学,功能类和运动能力的变化.

主要方法:

  • 20名患有PHT和CHD,不耐常规治疗的患者接受了慢性PGI2.2.
  • 血液动力学,NYHA功能类和运动能力在基线和一年后被测量.
  • 患者患有各种心脏病,包括心房隔膜缺陷,心室隔膜缺陷和其他疾病,有些人有残留的分流或之前的心脏手术.

主要成果:

  • 没有观察到对PGI2的急性反应.
  • 慢性PGI2显著降低了肺动脉平均压力 (21%的下降,P<0.01).
  • 在心脏指数 (3.5至5.9 L.min-1.m-2,P<0.01),肺血管抵抗 (25至12 U.m2,P<0.01) 和NYHA功能类 (3.2至2.0,P<0.0001) 中观察到改善.

更多相关视频

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

相关实验视频

Last Updated: Jul 12, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

  • 运动能力呈现改善趋势 (408至460米,P=0.13).

    • 结论:

    • 慢性PGI2的使用改善了PHT和相关的CHD患者的血液动力学和生活质量.
    • 这些发现表明,长期PGI2在与相关的CHD相关的PHT管理中起着重要作用,类似于其在初级PHT中的作用.